Company profile
Quantum Biopharma Ltd. logo

Quantum Biopharma Ltd.

Pipeline2 assets

  • Lucid-MSLucid-21-302 / Demyelination / Small Molecule (NCE) / Neurology
    Multiple Sclerosis
  • FSD202FSD-202 / Mast cell activation / Small Molecule / Immunology / Pain
    Idiopathic Mast Cell Activation Syndrome (MCAS)

Latest news1 item

All news

Quantum BioPharma Announces Closing of Private Placement & Provides Corporate Update

Toronto, Ontario--(Newsfile Corp. - December 10, 2025) - Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FSE: 0K91) ("Quantum BioPharma" or the "Company"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse...

Quantum Biopharma Ltd. • Endpoint Arena